Clinical trials: Buprenorphine
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome
HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)
STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are dependent on opioids. This study is funded by the National Institute on Drug Abuse (R01DA030768, Altice, PI; Taxman \& Lawson, Co-PIs) and is…
- Conditions
- Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
- Trial name
- NCT03583138
- Testing
- buprenorphine
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Yale University
Opioid Dependence
Probuphine Innovations for Clinical Effectiveness (PRINCE)
HITLAB will conduct a crossover study wherein participants will be asked to wear an actigraphy device continuously for 12 weeks.
- Trial name
- PRINCE (NCT02896660)
- Testing
- ActiGraph Link
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Healthcare Innovation Technology Lab
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
A Brief Negotiation Interview Chatbot to Improve Buprenorphine Engagement Among Justice-Involved Individuals
Primary Objective: Conduct pilot study to assess effects of brief negotiation interview (BNI) Chatbot among individuals involved in the Connecticut criminal justice system with opioid use disorder (OUD).
- Conditions
- Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Criminal Behavior
- Trial name
- BNICHAT (NCT04982627)
- Testing
- BNI Chatbot, OUD Education & Treatment Resources
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Center for Progressive Recovery, LLC
Healthy Volunteers
Pharmacokinetics and Pharmacodynamics of Buprenorphine in Healthy Volunteers
The purpose of this study is to determine the amount of buprenorphine and its metabolites in blood and urine after administration of 0.6 mg buprenorphine in healthy volunteers.
- Trial name
- NCT00347815
- Testing
- Buprenorphine
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Danish University of Pharmaceutical Sciences
Pancreatitis, Chronic
Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis.
This study aims to determine the optimal timing of endoscopic intervention after extracorporeal shock wave lithotripsy(ESWL) of chronic pancreatitis with pancreatic stones.
- Trial name
- TEST (NCT05270434)
- Testing
- time interval between ESWL and ERCP is 12h, time interval between ESWL and ERCP is greater than 12h, morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid (Analgesics)
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Changhai Hospital
Sickle Cell Disease
Assessing the Safety of Buprenorphine in People With Sickle Cell Disease
This study will assess the safety of changing pain medications (opioids) adult sickle cell patients take to another type of medication therapy (buprenorphine). Patients will be asked questions about their quality of life.
- Trial name
- NCT03492099
- Testing
- buprenorphine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Johns Hopkins University
Opioid Use Disorder
Extended-release Buprenorphine as a Novel Low-dose Induction Strategy
This is a clinical trial to characterize the safety and pharmacokinetics of using extended-release buprenorphine (XR-BUP) as a novel low-dose buprenorphine induction strategy.
- Trial name
- NCT06441604
- Testing
- Extended-release Buprenorphine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Brigham and Women's Hospital
Heroin Dependence, Morphine Dependence
Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1
The purpose of this study is to assess buprenorphine/naloxone versus clonidine for inpatient opiate detoxification.
- Conditions
- Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
- Trial name
- NCT00032955
- Testing
- Buprenorphine/naloxone
- Where
- 6 sites in United States
- Volunteers
- 163 people
- Sponsor
- University of California, Los Angeles
Moderate to Severe Opioid Use Disorder
INDV-6001 Multiple-Dose Pharmacokinetic Study
This is a multicentre, open-label, multiple dose study of INDV-6001 in adult participants with moderate or severe OUD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5).
- Trial name
- NCT06576843
- Testing
- INDV-6001, Suboxone, Sublocade
- Where
- 11 sites in United States
- Volunteers
- 123 people
- Sponsor
- Indivior Inc.
Opioid Use Disorder, Medication Adherence
MHealth Incentivized Adherence Plus Patient Navigation
Polysubstance use involving opioids and methamphetamine is emerging as a new public health crisis. Patients with opioids and methamphetamine use often experience serious medical complications requiring hospitalization, which…
- Conditions
- Opioid Use Disorder, Medication Adherence, Polysubstance Drug Use (Indiscriminate Drug Use), Methamphetamine-dependence
- Trial name
- MIAPP (NCT06027814)
- Testing
- Patient Navigation and mHealth (PN+mHealth)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
Opioid-Related Disorders, Opiate Dependence
Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Study P05603)
The aim of this post marketing surveillance study is to investigate the retention rate after 12 months of drug dependence treatment with SUBOXONE® (buprenorphine plus naloxone) of opioid dependent patients under real life…
- Conditions
- Opioid-Related Disorders, Opiate Dependence, Drug Abuse
- Trial name
- NCT00723749
- Testing
- Buprenorphine/Naloxone
- Volunteers
- 384 people
- Sponsor
- Indivior Inc.
Opioid Use Disorder, Poor Quality Sleep
Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD
This study is to develop and test a medical health application based on cognitive behavioral therapy for insomnia and augmented with other evidence-based sleep interventions that address common sleep-related problems in opioid…
- Trial name
- NCT06157840
- Testing
- mHealth application and sleep health education, Simplified mHealth application and sleep health education
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical University of South Carolina
Nicotine Use Disoder, Opioid Use Disorder
Effects of E-Cigarette Flavors on Adult E-Cigarette Users With Opioid Use Disorder
This study examines the effects of e-cigarette (EC) flavors among adults with opioid use disorder (OUD) receiving buprenorphine treatment who currently use e-cigarettes.
- Trial name
- FLAVOR (NCT07594717)
- Testing
- Sweet-cooling, Sweet non-cooling EC flavor, Tobacco flavor EC
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Prisma Health-Upstate
Opioid-Related Disorders
Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1
The purpose of this protocol is to to compare the clinical utility of two dosage tapering regimens in Buprenorphine/Naloxone stabilized subjects for opiate detoxification.
- Trial name
- NCT00078117
- Testing
- Buprenorphine
- Where
- 11 sites in United States
- Volunteers
- 516 people
- Sponsor
- University of California, Los Angeles
Opioid Use Disorder
Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.
The purpose of this clinical trial is to compare the effectiveness of office-based methadone with pharmacy administration and/or dispensing to office-based buprenorphine for the treatment of opioid use disorder.
- Trial name
- NCT06323824
- Testing
- Methadone, Buprenorphine (BUP)
- Where
- 6 sites in United States
- Volunteers
- 600 people
- Sponsor
- Yale University
Substance Use Disorders
Enhancing Addiction Treatment Through Psychoeducation
Addiction is a brain disorder characterized by a broad range of both apparent and subtle cognitive impairments in attention, memory, executive functions, and decision-making.
- Trial name
- NCT07178158
- Testing
- Installing the Metacognium software app, Continue treatment as usual
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Virginia Commonwealth University
Osteoarthritis
The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system and immediate release oxycodone/acetaminophen…
- Trial name
- NCT00315848
- Testing
- Buprenorphine transdermal delivery system
- Where
- 10 sites in United States
- Volunteers
- 225 people
- Sponsor
- Purdue Pharma LP
Opioid Use Disorder
Behavioral Optimization for Overcoming Suboptimal Treatment Retention (BUP-BOOSTeR)
Buprenorphine, a medication for opioid use disorder (MOUD), is associated with decreased opioid overdose and all-cause mortality.
- Trial name
- BUP-BOOSTeR (NCT07607743)
- Testing
- Behavioral Activation (BA), Attendance Reinforcement (AR), Peer-Delivered Motivational Interviewing (PDMI)
- Volunteers
- 240 people
- Sponsor
- Boston University
Opioid Use, Opioid Use Disorder
Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP
The purpose of this study is to provide medication for opioid use disorder (MOUD) with buprenorphine and naloxone, or bup/nx, pre-exposure prophylaxis (PrEP) for HIV prevention, and/or hepatitis C treatment for persons who inject…
- Conditions
- Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv
- Trial name
- PARTNERUP (NCT05108935)
- Testing
- Suboxone, Truvada, Mavyret
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Duke University
Postoperative Pain
Safety of the Buprenorphine Transdermal Delivery System in Subjects With Mod-to-Sev Pain Following Orthopedic Surgery.
The objective of this study is to assess the safety of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system in subjects with moderate to severe pain after orthopedic surgery.
- Trial name
- NCT00315835
- Testing
- Buprenorphine transdermal delivery system
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Purdue Pharma LP